{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:18:25Z","timestamp":1791389905728,"version":"4.3.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,16]]},"DOI":"10.7759\/cureus.105298","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:38:38Z","timestamp":1773657518000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Central Serous Chorioretinopathy With Topical Difluprednate: A Literature Review"],"prefix":"10.7759","author":[{"given":"Sayan K","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Khuddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100865","article-title":"Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities","volume":"79","author":"Kaye R","year":"2020","unstructured":"Kaye R, Chandra S, Sheth J, Boon CJ, Sivaprasad S, Lotery A. Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res. 2020, 79:100865. 10.1016\/j.preteyeres.2020.100865","journal-title":"Prog Retin Eye Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S220845","article-title":"Central serous chorioretinopathy: pathogenesis and management","volume":"13","author":"Semeraro F","year":"2019","unstructured":"Semeraro F, Morescalchi F, Russo A, et al.. Central serous chorioretinopathy: pathogenesis and management. Clin Ophthalmol. 2019, 13:2341-52. 10.2147\/OPTH.S220845","journal-title":"Clin Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-023-00349-y","article-title":"Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies","volume":"10","author":"Zhang X","year":"2023","unstructured":"Zhang X, Lim CZ, Chhablani J, Wong YM. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye Vis (Lond). 2023, 10:33. 10.1186\/s40662-023-00349-y","journal-title":"Eye Vis (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.92694","article-title":"Quality of life of patients with central serous chorioretinopathy - a major cause of vision threat among middle-aged individuals","volume":"17","author":"Karska-Basta I","year":"2021","unstructured":"Karska-Basta I, Pociej-Marciak W, Chrz\u0105szcz M, \u017buber-\u0141askawiec K, Sanak M, Romanowska-Dixon B. Quality of life of patients with central serous chorioretinopathy - a major cause of vision threat among middle-aged individuals. Arch Med Sci. 2021, 17:724-30. 10.5114\/aoms.2020.92694","journal-title":"Arch Med Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100264","article-title":"Current pharmacological treatment options for central serous chorioretinopathy: a review","volume":"13","author":"Nicol\u00f2 M","year":"2020","unstructured":"Nicol\u00f2 M, Desideri LF, Vagge A, Traverso CE. Current pharmacological treatment options for central serous chorioretinopathy: a review. Pharmaceuticals (Basel). 2020, 13:264. 10.3390\/ph13100264","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich A","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, et al.. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015, 48:82-118. 10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.09.003","article-title":"Therapies for central serous chorioretinopathy: a report by the American Academy of Ophthalmology","volume":"132","author":"Kim LA","year":"2025","unstructured":"Kim LA, Maguire MG, Weng CY, et al.. Therapies for central serous chorioretinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2025, 132:343-53. 10.1016\/j.ophtha.2024.09.003","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04486-w","article-title":"Corticosteroids usage and central serous chorioretinopathy: a meta-analysis","volume":"258","author":"Ge G","year":"2020","unstructured":"Ge G, Zhang Y, Zhang Y, Xu Z, Zhang M. Corticosteroids usage and central serous chorioretinopathy: a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2020, 258:71-7. 10.1007\/s00417-019-04486-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14201","article-title":"Central serous chorioretinopathy: a review","volume":"51","author":"Fung AT","year":"2023","unstructured":"Fung AT, Yang Y, Kam AW. Central serous chorioretinopathy: a review. Clin Exp Ophthalmol. 2023, 51:243-70. 10.1111\/ceo.14201","journal-title":"Clin Exp Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17249455","article-title":"Temporal association between topical ophthalmic corticosteroid and the risk of central serous chorioretinopathy","volume":"17","author":"Chang YS","year":"2020","unstructured":"Chang YS, Weng SF, Wang JJ, Jan RL. Temporal association between topical ophthalmic corticosteroid and the risk of central serous chorioretinopathy. Int J Environ Res Public Health. 2020, 17:9455. 10.3390\/ijerph17249455","journal-title":"Int J Environ Res Public Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-16360","article-title":"Associations between topical ophthalmic corticosteroids and central serous chorioretinopathy: a Taiwanese population-based study","volume":"56","author":"Chang YS","year":"2015","unstructured":"Chang YS, Weng SF, Chang C, Wang JJ, Wang JY, Jan RL. Associations between topical ophthalmic corticosteroids and central serous chorioretinopathy: a Taiwanese population-based study. Invest Ophthalmol Vis Sci. 2015, 56:4083-9. 10.1167\/iovs.14-16360","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000001211","article-title":"Potential treatment for peripapillary pachychoroid syndrome","volume":"17","author":"Pothof AB","year":"2023","unstructured":"Pothof AB, Fern\u00e1ndez-Avellaneda P, Behar-Cohen F, Martinez Ciriano JP, Yzer S. Potential treatment for peripapillary pachychoroid syndrome. Retin Cases Brief Rep. 2023, 17:425-9. 10.1097\/ICB.0000000000001211","journal-title":"Retin Cases Brief Rep"},{"key":"ref13","article-title":"Difluprednate and loratadine in the treatment of pachychoroid disease spectrum","volume":"66","author":"Vieta ER","year":"2025","unstructured":"Vieta ER, Au A, Ahn J, et al.. Difluprednate and loratadine in the treatment of pachychoroid disease spectrum. Invest Ophthalmol Visual Sci. 2025, 66:4677.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00385-1","article-title":"Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses","volume":"8","author":"Felipe CQ","year":"2022","unstructured":"Felipe CQ, Biancardi AL, Civile VT, Carvas Junior N, Serracarbassa PD, Koike MK. Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses. Int J Retina Vitreous. 2022, 8:34. 10.1186\/s40942-022-00385-1","journal-title":"Int J Retina Vitreous"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01338-4","article-title":"Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis","volume":"35","author":"Duan J","year":"2021","unstructured":"Duan J, Zhang Y, Zhang M. Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis. Eye (Lond). 2021, 35:1102-10. 10.1038\/s41433-020-01338-4","journal-title":"Eye (Lond)"},{"key":"ref16","unstructured":"Get serious about central serous chorioretinopathy. (2021). Accessed. 2026: https:\/\/www.reviewofoptometry.com\/article\/get-serious-about-central-serous-chorioretinopathy."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2014.4.280820132","article-title":"Difluprednate in ophthalmic practice","volume":"4","author":"Patel MM","year":"2014","unstructured":"Patel MM, Singhal D. Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol. 2014, 4:92-4. 10.5455\/njppp.2014.4.280820132","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1586\/17469899.3.6.619","article-title":"Difluprednate: changing the landscape of ocular pharmacology","volume":"3","author":"Korenfeld M","year":"2008","unstructured":"Korenfeld M. Difluprednate: changing the landscape of ocular pharmacology. Expert Rev Ophthalmol. 2008, 3:619-25. 10.1586\/17469899.3.6.619","journal-title":"Expert Rev Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2423869","article-title":"Review on the use of difluprednate in inflammatory eye disorders: the topical steroid that goes the distance","volume":"33","author":"Amer R","year":"2025","unstructured":"Amer R, Pillar S. Review on the use of difluprednate in inflammatory eye disorders: the topical steroid that goes the distance. Ocul Immunol Inflamm. 2025, 33:670-82. 10.1080\/09273948.2024.2423869","journal-title":"Ocul Immunol Inflamm"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins JP","year":"2024","unstructured":"Higgins JP, Morgan RL, Rooney AA, et al.. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024, 186:108602. 10.1016\/j.envint.2024.108602","journal-title":"Environ Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000356","article-title":"Incidence of acute exudative maculopathy after reduced-fluence photodynamic therapy","volume":"11","author":"Mammo Z","year":"2017","unstructured":"Mammo Z, Forooghian F. Incidence of acute exudative maculopathy after reduced-fluence photodynamic therapy. Retin Cases Brief Rep. 2017, 11:217-20. 10.1097\/ICB.0000000000000356","journal-title":"Retin Cases Brief Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1200492","article-title":"The role of inflammation in central serous chorioretinopathy: from mechanisms to therapeutic prospects","volume":"15","author":"Shen X","year":"2024","unstructured":"Shen X, Kong F, Wen J, Wang X, Huang C. The role of inflammation in central serous chorioretinopathy: from mechanisms to therapeutic prospects. Front Pharmacol. 2024, 15:1200492. 10.3389\/fphar.2024.1200492","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.5693\/djo.02.2015.05.004","article-title":"Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease","volume":"22","author":"Lu S","year":"2016","unstructured":"Lu S, Taban M. Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease. Digit J Ophthalmol. 2016, 22:54-7. 10.5693\/djo.02.2015.05.004","journal-title":"Digit J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2016.04.009","article-title":"Topical difluprednate for the treatment of retinal vasculitis associated with birdshot chorioretinitis","volume":"3","author":"Wang JC","year":"2016","unstructured":"Wang JC, Burkholder BM, Butler NJ. Topical difluprednate for the treatment of retinal vasculitis associated with birdshot chorioretinitis. Am J Ophthalmol Case Rep. 2016, 3:22-4. 10.1016\/j.ajoc.2016.04.009","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref26","article-title":"Distinguishing VKH from CSCR","author":"Padidam S","year":"2020","unstructured":"Padidam S, Brian K, Jordana G, et al.. Distinguishing VKH from CSCR. Retina Today. 2020, 22-4.","journal-title":"Retina Today"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.056","article-title":"Systemic corticosteroid use after central serous chorioretinopathy diagnosis","volume":"128","author":"Azad AD","year":"2021","unstructured":"Azad AD, Zhou M, Afshar AR, Bakri SJ, Pershing S. Systemic corticosteroid use after central serous chorioretinopathy diagnosis. Ophthalmology. 2021, 128:121-9. 10.1016\/j.ophtha.2020.06.056","journal-title":"Ophthalmology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107754","article-title":"Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: review of the pre-clinical and clinical evidence","volume":"187","author":"Bousquet E","year":"2019","unstructured":"Bousquet E, Zhao M, Daruich A, Behar-Cohen F. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: review of the pre-clinical and clinical evidence. Exp Eye Res. 2019, 187:107754. 10.1016\/j.exer.2019.107754","journal-title":"Exp Eye Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2011.47.5.1590791","article-title":"Difluprednate for inflammatory eye disorders","volume":"47","author":"Mulki L","year":"2011","unstructured":"Mulki L, Foster CS. Difluprednate for inflammatory eye disorders. Drugs Today (Barc). 2011, 47:327-33. 10.1358\/dot.2011.47.5.1590791","journal-title":"Drugs Today (Barc)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s4460","article-title":"The role of difluprednate ophthalmic emulsion in clinical practice","volume":"3","author":"Jamal KN","year":"2009","unstructured":"Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009, 3:381-90. 10.2147\/opth.s4460","journal-title":"Clin Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-12660","article-title":"Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study","volume":"55","author":"Sheppard JD","year":"2014","unstructured":"Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci. 2014, 55:2993-3002. 10.1167\/iovs.13-12660","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref32","article-title":"Effects of intraocular pressure and other factors on subretinal fluid resorption","volume":"28","author":"Negi A","year":"1987","unstructured":"Negi A, Kawano S, Marmor MF. Effects of intraocular pressure and other factors on subretinal fluid resorption. Invest Ophthalmol Vis Sci. 1987, 28:2099-102.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004109","article-title":"Prednisolone eye drops as a potential treatment in Nonneovascular pachychoroid-related diseases","volume":"44","author":"van den Tillaart FM","year":"2024","unstructured":"van den Tillaart FM, Temmerman IM, Hartgers F, Yzer S. Prednisolone eye drops as a potential treatment in Nonneovascular pachychoroid-related diseases. Retina. 2024, 44:1371-8. 10.1097\/IAE.0000000000004109","journal-title":"Retina"},{"key":"ref34","article-title":"Steroid Eye Drops in Chronic Central Serous Chorioretinopathy","year":"2022","unstructured":"Steroid Eye Drops in Chronic Central Serous Chorioretinopathy. ClinicalTrials.gov, Nijmegen, Netherlands; 2022."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449365-treatment-of-central-serous-chorioretinopathy-with-topical-difluprednate-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:38:40Z","timestamp":1773657520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449365-treatment-of-central-serous-chorioretinopathy-with-topical-difluprednate-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.105298","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}